MICHAEL ANTHONY WHITE - 29 May 2024 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
Chief Scientific Officer
Signature
/s/ Jason Throne, as Attorney-in-Fact for Michael Anthony White
Issuer symbol
IDYA
Transactions as of
29 May 2024
Net transactions value
-$666,374
Form type
4
Filing time
31 May 2024, 16:26:47 UTC
Previous filing
04 Mar 2024
Next filing
28 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $366,510 +28,500 $12.86 28,500 29 May 2024 Direct
transaction IDYA Common Stock Sale $1,001,588 -27,649 -97% $36.23 851 29 May 2024 Direct F1, F2
transaction IDYA Common Stock Sale $31,297 -851 -100% $36.78 0 29 May 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -28,500 -31% $0.000000 64,000 29 May 2024 Common Stock 28,500 $12.86 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on February 22, 2024.
F2 This transaction was executed in multiple trades in prices ranging from $35.68 to $36.655, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $36.68 to $36.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.